Which loop diuretic, torsemide or furosemide, is more effective for treating ascites?

Torsemide vs Furosemide for Ascites

Both torsemide and furosemide are acceptable loop diuretics for ascites management, with furosemide or bumetanide recommended as first-line intravenous agents in the inpatient setting, while torsemide may offer advantages in the outpatient setting despite being only available orally in the United States 1.

Guideline-Based Recommendations

The most recent 2025 AGA guidance explicitly states that furosemide and bumetanide likely offer similar efficacy as first-line agents for inpatient management of volume overload in cirrhosis 1. The guideline notes that torsemide may play a role in both inpatient and outpatient settings, though its oral-only availability in the U.S. limits inpatient use 1.

The 2021 AASLD practice guidance takes a neutral stance, stating that aldosterone antagonists and loop diuretics (furosemide, torsemide, bumetanide) are the mainstay of treatment, with a note that torsemide or bumetanide may improve natriuresis in patients with suboptimal response to furosemide 2.

Evidence from Clinical Studies

Pharmacokinetic Advantages of Torsemide

Older studies from the 1990s-2000s suggested torsemide had theoretical advantages:

• Greater 24-hour diuresis (2863 vs 2111 ml, p<0.01) and prolonged natriuresis in the 6-24 hour period 3
• Higher bioavailability and longer half-life 4, 5
• Better response in patients who showed weak response to furosemide 3

Critical 2025 Data Contradicts Earlier Findings

The most recent and highest quality evidence from 2025 (TRANSFORM-Mechanism trial) fundamentally challenges the superiority of torsemide 6. This multicenter mechanistic study found:

• Torsemide had significantly LOWER kidney bioavailability (17.1% vs 24.8%, p<0.001) 6
• Furosemide had LONGER duration of kidney drug delivery and natriuresis 6
• The commonly used 2:1 dose equivalence (40mg furosemide:20mg torsemide) resulted in substantially greater natriuresis with torsemide, but this was offset by:
  • Greater neurohormonal activation (increased renin, aldosterone, norepinephrine)
  • More kidney dysfunction
  • No improvement in plasma volume or body weight 6
• The actual dose equivalence for similar natriuresis was approximately 4:1 (40mg furosemide:10mg torsemide) 6

Long-term Efficacy Studies

A 2001 study showed torsemide and furosemide had similar long-term efficacy for ascites resolution, though fewer patients required dose escalation with torsemide (2 vs 9 patients, p<0.05) 7.

Practical Algorithm for Clinical Decision-Making

Inpatient Management

1. Start with IV furosemide or bumetanide in bolus (2-3 times daily) or continuous infusion 1
2. Initial furosemide dose: 40mg/day, escalate up to 160mg/day 2
3. Monitor response every 2-3 days with daily weights, volume status, kidney function 1
4. If suboptimal response to furosemide, consider switching to torsemide or bumetanide 2

Outpatient Management

1. Torsemide may be preferred due to:
   • Once-daily dosing (better compliance)
   • More predictable absorption 4
   • Use 10mg torsemide as equivalent to 40mg furosemide (based on 2025 data) 6
2. Combine with spironolactone 100-400mg/day 2

Critical Caveats

• Avoid excessive torsemide dosing: The 2025 data shows that higher doses lead to neurohormonal activation without additional benefit in fluid status 6
• Furosemide may interfere with tolvaptan efficacy: If using tolvaptan, keep furosemide ≤15mg/day 8
• Monitor for hepatic encephalopathy: Both drugs can precipitate encephalopathy through hypovolemia, hypokalemia, and metabolic alkalosis 9
• Always combine with aldosterone antagonist in hepatic disease to prevent hypokalemia 9

Bottom Line

The 2025 mechanistic data fundamentally undermines the theoretical advantages of torsemide, showing no meaningful pharmacokinetic/pharmacodynamic superiority and potential for harm from overdosing. Guidelines appropriately recommend furosemide as first-line, with torsemide reserved for outpatient convenience or furosemide non-responders, using conservative dosing (4:1 equivalence ratio).